Physician profile
James C Reed
NPI 1861699498
$824.92
in general payments reported to CMS, 2019-2025
13 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $210 · 2024: $312 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $798 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $797.65 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $95.70 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $89.36 | 2024-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $58.93 | 2023-2025 | Rexulti |
| Lundbeck LLC | $57.81 | 2024-2025 | Rexulti |
| Bausch Health US, LLC | $54.88 | 2023-2024 | Wellbutrin, Aplenzin |
| Orexo US, INC. | $54.79 | 2023-2024 | Zubsolv |
| Tris Pharma INC | $48.72 | 2023-2025 | Dyanavel Xr, Onyda Xr |
| Alkermes, INC. | $48.58 | 2023 | Aristada, Lybalvi |
| Janssen Pharmaceuticals, INC | $28.76 | 2025 | Spravato |
| Ironshore Pharmaceuticals INC. | $23.00 | 2023 | Jornay Pm |
| Noven Therapeutics, LLC | $20.16 | 2024 | Xelstrym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.24 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Reed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.